Tilray IPO
The first cannabis producer to IPO on a major US exchange, and the mechanics behind its dramatic 2018 bubble.
Tilray's IPO was genuinely historic as a venue first—but the September 2018 spike wasn't investor euphoria about cannabis. It was a textbook short squeeze: tiny public float, expensive borrow, few US alternatives. The stock crashed nearly 90% by year-end. Most retail buyers near the peak lost money; Privateer insiders did well on paper but faced lockup and distribution mechanics that ate into realized gains.
Background: Privateer, Nanaimo, and the path to Nasdaq
Tilray was incorporated as a subsidiary of Privateer Holdings, a Seattle-based private equity firm founded in 2010 by Brendan Kennedy, Christian Groh, and Michael Blue [1]. Privateer had built a portfolio including the cannabis strain database Leafly and the Marley Natural brand before turning Tilray into its flagship cultivator.
Tilray received one of Canada's earliest commercial cultivation licenses under the Marihuana for Medical Purposes Regulations (MMPR) and opened a 60,000-square-foot facility in Nanaimo, British Columbia in 2014 [2]. By 2018, with the Cannabis Act on track to legalize adult-use cannabis in Canada in October, Canadian cannabis producers were racing to raise capital. Most listed on the Toronto Stock Exchange or the TSX Venture Exchange. Tilray chose a different path: a direct IPO on the Nasdaq Global Select Market in the United States [1]. This made it structurally distinct from its peers, who had either Canadian-only listings or traded over-the-counter (OTC) in the United States.
The IPO: July 19, 2018
Tilray priced 9,000,000 Class 2 common shares at US$17.00 on July 18, 2018, at the top of its $14–$16 marketed range, and began trading on Nasdaq under the symbol TLRY on July 19, 2018 [1][3]. Gross proceeds were approximately US$153 million before the underwriters' overallotment option. Cowen and Company and BMO Capital Markets led the offering.
The listing's historical significance lay in venue, not size. Tilray became the first company whose primary business was growing and selling cannabis to complete a traditional IPO on a major US exchange. Strong evidence (Cannabis-adjacent pharmaceutical companies, such as GW Pharmaceuticals, had listed on Nasdaq earlier, and large Canadian producers traded OTC in the US, but no pure-play cannabis cultivator had achieved a major-exchange primary listing.)
Shares closed their first day at $22.39, up roughly 32%. The public float was unusually small: Privateer Holdings retained approximately 75 million of the roughly 93 million shares outstanding, and those shares were locked up for 180 days under the IPO lock-up agreement [1]. Only about 17–18 million shares were actually available to trade.
The September 2018 short squeeze
Between July and mid-September 2018, TLRY rose steadily on news flow: a US Drug Enforcement Administration import authorization for a clinical trial, a distribution partnership with Sandoz Canada, and rising anticipation of Canadian adult-use legalization on October 17, 2018.
The dramatic move came on September 19, 2018. Shares opened around $233, traded as high as $300 intraday, triggered multiple Nasdaq volatility halts, and closed at $214.06—a one-day gain of roughly 38% and a market capitalization of approximately US$20 billion [4]. The company had reported approximately US$20 million in revenue and operated at a net loss in 2017 [1].
Analysts and financial journalists attributed the move to a textbook short squeeze. Borrow fees on TLRY had climbed to triple-digit annualized rates, the publicly available float was tiny, and US retail investors looking for cannabis exposure on a major exchange had few alternatives. Strong evidence Tilray CEO Brendan Kennedy appeared on CNBC during the rally, and the stock began falling almost immediately after. By year-end 2018 it traded near $70, and by the time Privateer's lockup-related shares were distributed in 2019 the price had fallen further.
After the bubble: dilution, mergers, and strategic shifts
Tilray never recaptured its 2018 peaks. Key milestones:
- January 2019: The 180-day lock-up on Privateer's shares expired, permitting their distribution to Privateer's investors and accelerating downward price pressure.
- December 2020: Tilray and Aphria announced an all-stock merger. The deal closed on May 3, 2021, with the combined company retaining the Tilray name and TLRY ticker [5]. Aphria CEO Irwin Simon became chairman and CEO of the merged entity. Legally, Tilray was the surviving entity and kept the ticker, but Aphria shareholders received approximately 62% of the combined company, leading most analysts to describe it as a reverse merger in substance [5]. Strong evidence
- September 2023: Tilray announced the acquisition of a portfolio of craft beer brands from Anheuser-Busch InBev, repositioning as a 'consumer packaged goods' company with segments in cannabis, beverage alcohol, and wellness [6].
- 2024: Heavy share issuance to fund acquisitions pushed the share count from roughly 93 million at IPO to over 900 million by 2024, and management signaled potential reverse splits to maintain Nasdaq listing compliance [7].
Brendan Kennedy stepped down as CEO at the time of the Aphria merger. Privateer Holdings was effectively wound down through a 2019 reorganization that distributed its Tilray shares to its investors.
Myths and misreadings
Several persistent stories about the Tilray IPO warrant correction:
'Tilray was the first cannabis company on a major US exchange.' It was the first pure-play cannabis producer to IPO on a major US exchange. Cannabis-adjacent pharmaceutical companies—such as GW Pharmaceuticals, which developed the cannabinoid drug Epidiolex—had been listed on Nasdaq since 2013. Large Canadian cannabis producers also traded over-the-counter in the US earlier. Tilray's distinction was specifically a direct listing of a vertically integrated cultivation-and-retail operator on Nasdaq. Strong evidence
'The September spike proved investor confidence in cannabis.' Contemporary financial reporting and later retrospective analysis characterize September 2018 as a mechanical short squeeze driven by a tiny float and high borrow costs, not a fundamental revaluation of the cannabis sector. Strong evidence
'Tilray made early investors rich.' Privateer Holdings and pre-IPO shareholders did very well on paper at the September 2018 peak. However, 180-day lock-up restrictions, the mechanics of share distribution to Privateer's equity holders, and the subsequent price decline meant most realized returns were a fraction of the mark-to-market value at the spike. Retail investors who bought shares near the September top—or who held through the subsequent years—suffered large losses. Strong evidence
'The 2021 Aphria merger was Tilray buying a competitor.' Although Tilray was the surviving legal entity and retained the name and ticker, Aphria shareholders received approximately 62% ownership of the combined company, and Aphria's CEO took the helm. Most equity analysts and financial commentators described the transaction as a reverse merger in economic substance [5]. Strong evidence
Sources
- Government Tilray, Inc. Form S-1 Registration Statement and amendments, filed with the U.S. Securities and Exchange Commission, January 18, 2018 through July 2018.
- Government Health Canada. Licensed Producers under the Marihuana for Medical Purposes Regulations (historical registry).
- Reported Kary, T. (2018). 'Pot Producer Tilray Surges 32% in First U.S. IPO on Nasdaq.' Bloomberg, July 19, 2018.
- Reported Egan, M. (2018). 'Pot stock Tilray briefly tops $300, then crashes.' CNN Business, September 19, 2018.
- Reported Berke, J. (2021). 'Tilray and Aphria complete merger to form world's largest cannabis company by revenue.' Reuters, May 3, 2021.
- Reported Maloney, J. (2023). 'Tilray to Buy Craft-Beer Brands from Anheuser-Busch InBev.' The Wall Street Journal, August 7, 2023.
- Government Tilray Brands, Inc. Annual Reports on Form 10-K, filed with the U.S. Securities and Exchange Commission, fiscal years 2022–2024.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Aphria RX (Tilray Deutschland) — German medical cannabis cultivator and Tilray Brands subsidiary operating under BfArM cont...
- Tilray Brands — Publicly traded holding company operating cannabis and beverage brands across multiple jur...